Neutralizing antibody responses for stage 3
pre-S, subvariants
Stage 3 participants were boosted with one of three pre-S DTM AS03 protein vaccine products, including the prototype vaccine, a monovalent Beta vaccine and a bivalent Beta + prototype vaccine (Table PsVN Ab GMT estimates at day 29 after vaccination with Sanofi variant vaccines were similar between older and younger adults and approximately 2–5 times higher in participants who were previously infected compared with those who were uninfected (Fig. Similar or a trend of modestly more durable antibody responses were seen in PsVN Ab titers from day 29 to day 91 with Beta-containing vaccines against Omicron subvariants (GMFD